U.S. Food and Drug Administration (FDA) approves Lilly's Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with type 2 diabetes
PR Newswire•24/09/2026•06:45 ET
0
U.S. Food and Drug Administration (FDA) approves Lilly's Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with type 2 diabetes PR Newswire
Onswik is designed to reduce injections by over 300 per year versus once-daily basal insulin(1,2)
Get started
Create a free account to read the full story and Whiz Insights.